Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 3:23 PM ET

Company Overview of Zenith Epigenetics Corp.

Company Overview



Key Executives for Zenith Epigenetics Corp.

Chief Executive Officer, President and Director
Age: 56
Chief Financial Officer
Chief Medical Officer
Senior Vice President of Operations
Chief Business Officer
Compensation as of Fiscal Year 2014.

Zenith Epigenetics Corp. Key Developments

Zenith Epigenetics Corp. Announces Suspension of its Clinical Development Efforts with ZEN-3365

Zenith Epigenetics Corp. announced that due to recent business developments it is suspending its clinical development efforts with ZEN-3365, one of its proprietary BET inhibitors. This decision is unrelated to the preclinical safety and efficacy attributes of ZEN-3365. The company will continue to aggressively advance preclinical development activities with another differentiated proprietary small molecule BET inhibitor and is targeting the second half of 2015 to initiate Phase 1 clinical trials in oncology.

Zenith Epigenetics Corp Announces Management Changes

Zenith Epigenetics Corp. announced that it has appointed Joy Zhu as Chief Medical Officer, Sanjay Lakhotia as Chief Business Officer, and Michael Yakes as Vice President Drug Discovery and Exploratory Development. Prior to joining Zenith, Dr. Zhu held leadership positions at SUGEN/Pfizer, SBIO Pte Ltd, Amgen, JNJ, and Novartis. Most recently, Dr. Zhu led oncology clinical development at Halozyme Therapeutics.

Zenith Epigenetics Corp., Annual General Meeting, Oct 08, 2014

Zenith Epigenetics Corp., Annual General Meeting, Oct 08, 2014., at 10:30 Mountain Daylight. Location: TELUS Convention Centre, , The Glen Room 206. Agenda: To receive the audited financial statements of the company for the year ended April 30, 2014 and the report of the auditors thereon; to set the number of directors to be elected at the Meeting at six; to elect directors for the ensuing year; to appoint auditors for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and to transact such other business that may properly come before the meeting or adjournments thereof.

Similar Private Companies By Industry

Company Name Region
Mgn Constructors Inc Americas
1254916 Alberta Ltd Americas
Gary L. Redhead Holdings Ltd. Americas
Peters, Brown LLP Americas
Seajay Management Enterprises Ltd. Americas

Recent Private Companies Transactions

Private Placement
July 23, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zenith Epigenetics Corp., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at